华法林药物遗传学在代表性不足的少数群体中的未来。
The future of warfarin pharmacogenetics in under-represented minority groups.
作者信息
Cavallari Larisa H, Perera Minoli A
机构信息
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, 833 South Wood Street, Chicago, IL 60612-7230, USA.
出版信息
Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31.
Abstract
Genotype-based dosing recommendations are provided in the US FDA-approved warfarin labeling. However, data that informed these recommendations were from predominately Caucasian populations. Studies show that variants contributing to warfarin dose requirements in Caucasians provide similar contributions to dose requirements in US Hispanics, but significantly lesser contributions in African-Americans. Further data demonstrate that variants occurring commonly in individuals of African ancestry, but rarely in other racial groups, significantly influence dose requirements in African-Americans. These data suggest that it is important to consider variants specific for African-Americans when implementing genotype-guided warfarin dosing in this population.
摘要
美国食品药品监督管理局（FDA）批准的华法林标签中提供了基于基因型的给药建议。然而，形成这些建议的数据主要来自白种人群体。研究表明，影响白种人对华法林剂量需求的基因变异，对美国西班牙裔人群的剂量需求也有类似影响，但对非裔美国人的剂量需求影响明显较小。进一步的数据表明，常见于非洲裔个体但很少见于其他种族群体的基因变异，显著影响非裔美国人的剂量需求。这些数据表明，在该人群中实施基因型指导的华法林给药时，考虑非裔美国人特有的基因变异非常重要。
相似文献
1
The future of warfarin pharmacogenetics in under-represented minority groups.华法林药物遗传学在代表性不足的少数群体中的未来。
Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31.
2
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.CYP2C9*8 在非裔美国人中较为常见：对药物遗传学剂量的影响。
Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.
3
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.利用与电子健康记录相关联的 DNA 样本预测欧洲裔美国人和非裔美国人的华法林剂量。
Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13.
4
Factors influencing warfarin dose requirements in African-Americans.影响非裔美国人华法林剂量需求的因素。
Pharmacogenomics. 2007 Nov;8(11):1535-44. doi: 10.2217/14622416.8.11.1535.
5
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.与非裔美国人华法林剂量相关的遗传变异：全基因组关联研究。
Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.
6
Pharmacogenomics of warfarin dose requirements in Hispanics.华法林剂量需求的药物基因组学：西班牙裔人群研究
Blood Cells Mol Dis. 2011 Feb 15;46(2):147-50. doi: 10.1016/j.bcmd.2010.11.005. Epub 2010 Dec 24.
7
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.细胞色素P450同工酶CYP2C9和维生素K环氧化物还原酶复合体亚基1的基因型共同决定华法林稳定剂量：一项前瞻性研究。
J Thromb Thrombolysis. 2006 Dec;22(3):191-7. doi: 10.1007/s11239-006-9030-7.
8
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.CYP2C9和VKORC1对华法林治疗起始阶段反应的影响。
Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.
9
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.种族和民族群体中 CYP2C9、VKORC1 和 CYP4F2 的联合频率。
Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49.
10
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.在印度尼西亚人群中，与 VKORC1、CYP2C9、CYP2C19 和 CYP4F2 基因变异相关的低剂量华法林反应。
Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2.
引用本文的文献
1
The impact of , , and polymorphisms on warfarin dose requirement in Saudi patients.[基因名称1]、[基因名称2]和[基因名称3]多态性对沙特患者华法林剂量需求的影响。
Front Pharmacol. 2025 Apr 30;16:1547142. doi: 10.3389/fphar.2025.1547142. eCollection 2025.
2
"I Have Come Because I See You Care About Me": Recruiting Older Black Americans for Genomic Research.“我之所以来，是因为我看到你们关心我”：为基因组研究招募老年非裔美国人。
Ethn Dis. 2024 Oct 22;34(4):185-191. doi: 10.18865/EthnDis-2023-75. eCollection 2024 Oct.
3
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.非裔患者稳定华法林剂量的全基因组关联研究的荟萃分析。
Blood Adv. 2024 Oct 22;8(20):5248-5261. doi: 10.1182/bloodadvances.2024014227.
4
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.撒哈拉以南非洲黑人患者华法林对映体和代谢物血浆浓度的全基因组关联研究。
Front Pharmacol. 2022 Sep 23;13:967082. doi: 10.3389/fphar.2022.967082. eCollection 2022.
5
Ethnic Diversity and Warfarin Pharmacogenomics.种族多样性与华法林药物基因组学
Front Pharmacol. 2022 Apr 4;13:866058. doi: 10.3389/fphar.2022.866058. eCollection 2022.
6
Pharmacogenomics in Cardiovascular Diseases.心血管疾病的药物基因组学。
Curr Protoc. 2021 Jul;1(7):e189. doi: 10.1002/cpz1.189.
7
Warfarin dosing algorithms: A systematic review.华法林剂量算法：系统评价。
Br J Clin Pharmacol. 2021 Apr;87(4):1717-1729. doi: 10.1111/bcp.14608. Epub 2020 Nov 18.
8
The Translational Approaches to Personalized Health Collaborative: Pharmacogenomics for African American Older Adults.转化医学个体化健康合作组织：非裔美国老年人的药物基因组学。
Clin Transl Sci. 2021 Mar;14(2):437-444. doi: 10.1111/cts.12885. Epub 2020 Oct 7.
9
The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.CYP450 药物代谢在精准心脏肿瘤学中的作用。
Int J Mol Sci. 2020 Jan 17;21(2):604. doi: 10.3390/ijms21020604.
10
Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province.VKORC1 基因多态性与华法林剂量需求及患者华法林基因多态性频率的相关性。
在伊朗克尔曼省的患者中。
Pharmacogenomics J. 2020 Aug;20(4):574-578. doi: 10.1038/s41397-019-0146-5. Epub 2020 Jan 6.
本文引用的文献
1
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.CYP2C9 R150H(*8) 多态性导致华法林清除率降低。
Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29.
2
The limits of genome-wide methods for pharmacogenomic testing.全基因组方法在药物基因组学检测中的局限性。
Pharmacogenet Genomics. 2012 Apr;22(4):261-72. doi: 10.1097/FPC.0b013e328350ca5f.
3
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.执行摘要：《抗栓治疗与血栓形成预防》第9版：美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):7S-47S. doi: 10.1378/chest.1412S3.
4
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.华法林剂量的药物遗传学调整在治疗一周后仍然受到遗传因素的显著影响。
Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21.
5
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.GGCX（CAA）16/17 重复多态性与非裔美国人需要更高剂量华法林的关联。
Pharmacogenet Genomics. 2012 Feb;22(2):152-8. doi: 10.1097/FPC.0b013e32834f288f.
6
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.药物基因组学在传统和新型口服抗凝药物管理中的作用。
Pharmacotherapy. 2011 Dec;31(12):1192-207. doi: 10.1592/phco.31.12.1192.
7
Emergency hospitalizations for adverse drug events in older Americans.老年人因药物不良反应而紧急住院的情况。
N Engl J Med. 2011 Nov 24;365(21):2002-12. doi: 10.1056/NEJMsa1103053.
8
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.临床药物遗传学实施联盟 CYP2C9 和 VKORC1 基因分型及华法林剂量指南。
Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7.
9
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.基于细胞的方法发现铂类药物敏感性相关种系多态性及其与卵巢癌患者结局的相关性分析。
Clin Cancer Res. 2011 Aug 15;17(16):5490-500. doi: 10.1158/1078-0432.CCR-11-0724. Epub 2011 Jun 24.
10
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.原发性人肝组织中表达数量性状基因座的鉴定、复制和功能精细定位。
PLoS Genet. 2011 May;7(5):e1002078. doi: 10.1371/journal.pgen.1002078. Epub 2011 May 26.
Zotero 插件